Overview

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged randomized double-blind trial.
Phase:
Phase 2
Details
Lead Sponsor:
Li Peng
Collaborators:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.